- Entry
- $4.23
- Now
- $4.22 -0.1%
- Target
- —
- Score
- —
Galectin Therapeutics (GALT) is a clinical-stage biotech with one drug, belapectin, for MASH cirrhosis with portal hypertension (severe liver scarring plus dangerous high blood pressure in the liver's veins). Stock jumped over 25% on June 24 after the company announced that the FDA had agreed on the design for a Phase 3 trial. https://preview.redd.it/krnw56axhd9h1.png?width=973&format=png&auto=webp&s=635995e389a936ccb89519b9a5eb9f679d9ff169 # The Chairman owns this company through debt GALT carries $135.7M of debt, entirely owed to one person: Chairman Richard Uihlein (the Uline shipping-supplies billionaire). It …
— ORIGINAL POST ·
$GALT - Galectin Therapeutics: FDA cleared a single-trial path to approval. The company can't afford to run it.
· r/pennystocks
· Jun 25, 2026